Durable Medical Equipment MarketSize, Share & Industry Analysis, 2026-2034By ProductBy End-useBy Distribution ChannelBy Payment/reimbursement TypeBy Age Group

Durable medical equipment covers devices intended for repeated, extended use by patients recovering from injury, managing chronic conditions, or requiring daily functional support, spanning mobility aids, patient handling and hygiene equipment, respiratory and monitoring devices, and infusion and therapeutic systems. These products are built to withstand sustained use in hospitals, nursing facilities, and private homes rather than single-use clinical settings. Buyers range from hospitals and long-term care operators purchasing at scale to individual patients and caregivers acquiring equipment directly or through insurance-linked rental and purchase programs.

Growth of 6.12% a year carries the global durable medical equipment market from USD 235 billion in 2025 to USD 400 billion in 2034. The full series behind that rate covers USD 178 billion in 2020, USD 221.8 billion in 2024, USD 248.5 billion in 2026 and USD 315.18 billion in 2030, with 2025 as the base year.

14% of 2025 revenue sits in Wheelchairs, worth USD 32.9 billion and rising to USD 50 billion at 12.5% by 2034, the largest product line in both years. Growth is fastest in Monitoring And Therapeutic Devices at 8.52% and slowest in Others Equipment at -10.02%. Mattress & Bedding Devices, Monitoring And Therapeutic Devices, Blood Glucose Monitors, Continuous Passive Motion (CPM), Infusion Pumps Market, Nebulizers and Oxygen Equipment take share over the period; Wheelchairs, Scooters, Walker And Rollators, Cranes And Crutches, Door Openers, Other Devices, Commodes And Toilets, Suction Pumps, Traction Equipment and Others Equipment give it up while still growing in absolute terms.

The end-use split puts Home Healthcare first, at USD 89.3 billion and 38% of revenue in 2025, rising to USD 172 billion and 43% in 2034. It is also the fastest-growing line on this axis at 7.56%, so the split concentrates over the period instead of balancing. It cuts the same total as the product axis from a different commercial angle, so revenue does not add across the two.

North America is the largest region at 38% of 2025 revenue, worth USD 89.3 billion and reaching USD 138 billion by 2034. Europe follows at 26.5%, moving from USD 62.28 billion to USD 99.2 billion, and Middle East and Africa is the smallest at 5%. Share shifts toward Asia Pacific, Latin America and Middle East and Africa over the forecast period, so the regional split repays a close reading.

Coverage extends to five regions, 17 product lines and five segmentation axes over the full fifteen years. The 2025 total itself is a triangulation of published figures and category proxies, short of a directly sourced total, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.

• The global durable medical equipment market moves from USD 178 billion in 2020 to USD 235 billion in 2025 and USD 400 billion by 2034, the forecast period compounding at 6.12% a year.
• Wheelchairs is the largest product line at USD 32.9 billion in 2025, a 14% share, reaching USD 50 billion and 12.5% of revenue by 2034.
• Monitoring And Therapeutic Devices is the fastest-growing line at 8.52%, lifting its share from 8% in 2025 to 9.8% in 2034 and its revenue from USD 18.8 billion to USD 39.2 billion.
• The bull case puts 2034 revenue at USD 414.4 billion and the bear case at USD 382 billion, either side of the USD 400 billion base case, each with its own stated assumption in the full report.
• North America holds 38% of global revenue in 2025 at USD 89.3 billion, the largest of the five regions tracked, and reaches USD 138 billion by 2034.
• Within North America, the United States is the worked country example, at USD 75.91 billion in 2025; 85.01% of regional revenue in the base year, and USD 117.3 billion by 2034.
• The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.

Three movements define the forecast period in the global durable medical equipment market: how the product mix changes, where regional weight shifts, and the rate at which the total compounds.

All three are changes in mix, not in direction: nothing contracts, and the movement is in which lines and regions absorb the new revenue.

Monitoring And Therapeutic Devices grows at more than twice the pace of Others Equipment. 8.52% against -10.02%: that gap, between Monitoring And Therapeutic Devices and Others Equipment, is the largest on the product axis. By 2034 the two sit at 9.8% and 1.1% of revenue, against 8% and 4.5% in 2025. In absolute terms Monitoring And Therapeutic Devices rises from USD 18.8 billion to USD 39.2 billion, while Others Equipment rises from USD 10.58 billion to USD 4.4 billion. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.

Regional weight shifts toward Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 24.5% of revenue in 2025 to 29% in 2034, worth USD 57.58 billion rising to USD 116 billion; Latin America moves from 6% of revenue in 2025 to 6.5% in 2034, worth USD 14.1 billion rising to USD 26 billion; Middle East and Africa moves from 5% of revenue in 2025 to 5.2% in 2034, worth USD 11.75 billion rising to USD 20.8 billion. Share moves off the others in turn: North America at 38% moving to 34.5%, Europe at 26.5% moving to 24.8%, each still growing in revenue terms. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.

The series never breaks trajectory. Year by year the total runs USD 178 billion in 2020, USD 221.8 billion in 2024, USD 235 billion in 2025, USD 248.5 billion in 2026, USD 315.18 billion in 2030 and USD 400 billion in 2034. Against 5.71% through the historical period, the 6.12% forecast rate is a continuation; no year in the series interrupts it. The risk in the number sits in the mix assumptions, not in whether the market grows at all, which is where the product and regional sections come in.

The fastest line decides the blended rate

The 6.12% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the product axis, and where regional growth is concentrated.

Downside case: USD 382 billion by 2034, against USD 400 billion in the base case

What the bull case turns on

The total depends on a single line

In North America, 38% of global revenue puts 2025 at USD 89.3 billion rising to USD 138 billion in 2034. That makes it the first-largest region covered, in 2025 and again in 2034.

Share settles at 34.5% in 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

Segment composition follows the global pattern: Wheelchairs largest at 14% of 2025 revenue, Monitoring And Therapeutic Devices fastest at 8.52%. Revenue for North America is broken out by every segmentation axis and by country in the full report.

The United States is the largest market within North America, generating USD 75.91 billion in 2025 and projected to reach USD 117.3 billion by 2034. 85.01% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. Against regional totals of USD 89.3 billion in 2025 and USD 138 billion in 2034, it is the country the full report breaks out in detail.

Composition here matches the global split: the largest line is Wheelchairs at 14% of 2025 revenue, easing to 12.5% by 2034, and the fastest is Monitoring And Therapeutic Devices at 8.52%, from 8% to 9.8%. Because the country carries 85.01% of North America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. The full report reports the United States by product separately.

In the United States, durable medical equipment falls under the Food and Drug Administration's device framework, with most wheelchairs, hospital beds, and oxygen concentrators classified in ways that determine whether a supplier files a premarket notification or relies on general controls alone. Suppliers seeking Medicare reimbursement must also meet the Centers for Medicare and Medicaid Services' quality standards for DMEPOS suppliers, typically demonstrated through accreditation by a CMS-approved body. Manufacturers operate under the FDA's quality system regulation, covering design controls, complaint handling, and corrective action. Labelling must identify intended use and any warnings a clinician or caregiver needs before the device reaches a home setting.

The suppliers tracked in this study (Invacare Corporation, ArjoHuntleigh, Stryker Corporation, Hill Rom, Inc., Drive Medical, GF Health Products, Inc., Sunrise Medical, Medline Industries, Hill Rom, Inc., Carex Health Brands, Inc, Becton, Dickinson and Company, General Electric Company, Medtronic PLC, Compass Health Brands, Getinge AB and Resmed Inc.) compete in the United States across the product lines above. Volume sits in Wheelchairs at 14% of 2025 revenue; movement sits in Monitoring And Therapeutic Devices at 8.52% growth. Per-company positioning and share at country level are in the full report only.

Within North America, Canada accounts for 15.01% of regional revenue and 5.7% of the global total, worth USD 13.4 billion in 2025 and USD 20.7 billion by 2034.

USD 62.28 billion of 2025 revenue is generated in Europe, 26.5% of the global durable medical equipment market on the way to USD 99.2 billion by 2034. Among the five regions it ranks second by revenue in both years.

Its share moves to 24.8% by 2034, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Segment composition follows the global pattern: Wheelchairs largest at 14% of 2025 revenue, Monitoring And Therapeutic Devices fastest at 8.52%. Per-axis and per-country detail for Europe sits in the full report.

The largest single market in Europe is Germany, at USD 17.44 billion in 2025 and USD 27.78 billion in 2034. Its 28% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. The region itself runs USD 62.28 billion to USD 99.2 billion over the same period, and this is the market carrying the country-level detail in the full report.

Germany buys along the same lines as the market globally; Wheelchairs first at 14% of 2025 revenue and 12.5% in 2034, Monitoring And Therapeutic Devices fastest at 8.52% on a share moving from 8% to 9.8%. Since 28% of Europe's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Revenue by product for Germany is reported separately in the full report.

In Germany, durable medical equipment is regulated as a medical device under the EU Medical Device Regulation, which requires manufacturers to classify each product according to the risk it poses and to secure a CE mark before it can be placed on the market. Higher-risk items typically need assessment by a Notified Body, while all suppliers must maintain technical documentation and a quality management system aligned with the regulation's requirements. The Federal Institute for Drugs and Medical Devices oversees market surveillance and vigilance reporting nationally. Labelling and instructions for use must be provided in German, covering intended purpose, handling, and any precautions relevant to home or clinical use.

Competition in Germany runs between the suppliers this study tracks: Invacare Corporation, ArjoHuntleigh, Stryker Corporation, Hill Rom, Inc., Drive Medical, GF Health Products, Inc., Sunrise Medical, Medline Industries, Hill Rom, Inc., Carex Health Brands, Inc, Becton, Dickinson and Company, General Electric Company, Medtronic PLC, Compass Health Brands, Getinge AB and Resmed Inc.. Volume sits in Wheelchairs at 14% of 2025 revenue; movement sits in Monitoring And Therapeutic Devices at 8.52% growth. A supplier weighted toward Europe is competing over a base of USD 62.28 billion in 2025 reaching USD 99.2 billion by 2034, 26.5% of global revenue at the start of that period.

5.83% of global revenue is generated in the United Kingdom; USD 13.7 billion in 2025, reaching USD 21.82 billion in 2034, and 22% of Europe.

4.77% of global revenue is generated in France; USD 11.21 billion in 2025, reaching USD 17.86 billion in 2034, and 18% of Europe.

USD 57.58 billion of 2025 revenue is generated in Asia Pacific, 24.5% of the global durable medical equipment market with USD 116 billion projected for 2034. It is a leading region on this axis, third by revenue throughout the period.

Share climbs to 29% by 2034, so the region grows faster than the market's 6.12% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Wheelchairs leads here as it does globally, at 14% of 2025 revenue, and Monitoring And Therapeutic Devices again grows fastest at 8.52%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.

USD 20.15 billion of Asia Pacific's 2025 revenue is generated in China, the region's largest market, reaching USD 40.6 billion by 2034. At 35% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. Set against USD 57.58 billion and USD 116 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Composition here matches the global split: the largest line is Wheelchairs at 14% of 2025 revenue, easing to 12.5% by 2034, and the fastest is Monitoring And Therapeutic Devices at 8.52%, from 8% to 9.8%. Its 35% weight in Asia Pacific means those movements carry straight into the regional totals. China carries its own product breakdown in the full report.

In China, durable medical equipment is regulated by the National Medical Products Administration, which assigns each device to a risk-based class that determines whether registration, filing, or a simpler notification pathway applies. Higher-risk items generally require clinical evaluation and a registration certificate before sale, while lower-risk equipment may proceed through provincial filing with local authorities. Manufacturers must operate under a quality management system consistent with national standards for medical devices, and imported equipment is subject to additional scrutiny of its manufacturing site and documentation. Labelling and instructions must appear in Chinese and clearly state intended use, contraindications, and storage or handling requirements for the equipment.

In China the field is Invacare Corporation, ArjoHuntleigh, Stryker Corporation, Hill Rom, Inc., Drive Medical, GF Health Products, Inc., Sunrise Medical, Medline Industries, Hill Rom, Inc., Carex Health Brands, Inc, Becton, Dickinson and Company, General Electric Company, Medtronic PLC, Compass Health Brands, Getinge AB and Resmed Inc.. Wheelchairs, at 14% of 2025 revenue, is where the volume sits, and Monitoring And Therapeutic Devices, growing at 8.52%, is where position changes hands over the forecast period. A supplier weighted toward Asia Pacific is competing over a base of USD 57.58 billion in 2025 reaching USD 116 billion by 2034, 24.5% of global revenue at the start of that period.

Japan is sized at USD 12.67 billion in 2025, rising to USD 25.52 billion by 2034; 5.39% of global revenue and 22.01% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

Within Asia Pacific, India accounts for 15.01% of regional revenue and 3.68% of the global total, worth USD 8.64 billion in 2025 and USD 17.4 billion by 2034.

In Latin America, 6% of global revenue puts 2025 at USD 14.1 billion and reaches USD 26 billion by 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.

Share climbs to 6.5% by 2034, at a pace above the 6.12% global rate, so this region warrants separate treatment and should not be scaled off the total.

The product mix reported at global level applies here, with Wheelchairs the largest line at 14% of 2025 revenue and Monitoring And Therapeutic Devices the fastest-growing at 8.52%. The full report breaks Latin America out along every axis and by country.

The largest single market in Latin America is Brazil, at USD 6.35 billion in 2025 and USD 11.7 billion in 2034. Its 45.04% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. Regional revenue of USD 14.1 billion in 2025 and USD 26 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in Brazil follows the product mix reported at global level: Wheelchairs is the largest line at 14% of 2025 revenue, moving to 12.5% by 2034, while Monitoring And Therapeutic Devices grows fastest at 8.52% and takes its share from 8% to 9.8%. Its 45.04% weight in Latin America means those movements carry straight into the regional totals. Revenue by product for Brazil is reported separately in the full report.

In Brazil, durable medical equipment is regulated by Anvisa, the national health surveillance agency, which requires products to be registered or notified depending on the risk classification assigned to the device. Manufacturers and importers must hold Good Manufacturing Practice certification for the relevant facility, and technical files must demonstrate conformity with applicable national and harmonized standards before a product can be marketed. Anvisa also administers post-market vigilance, requiring suppliers to report adverse events and field actions. Labelling must be in Portuguese and identify the manufacturer, intended use, and any handling or storage conditions a caregiver or clinician needs to observe.

The suppliers tracked in this study (Invacare Corporation, ArjoHuntleigh, Stryker Corporation, Hill Rom, Inc., Drive Medical, GF Health Products, Inc., Sunrise Medical, Medline Industries, Hill Rom, Inc., Carex Health Brands, Inc, Becton, Dickinson and Company, General Electric Company, Medtronic PLC, Compass Health Brands, Getinge AB and Resmed Inc.) compete in Brazil across the product lines above. The commercially relevant division is 14% of 2025 revenue in Wheelchairs, where the volume is, against 8.52% growth in Monitoring And Therapeutic Devices, where share moves. Weighting toward Latin America means competing for 6% of 2025 global revenue, a base of USD 14.1 billion moving to USD 26 billion across the forecast period.

Mexico is sized at USD 4.23 billion in 2025, rising to USD 7.8 billion by 2034; 1.8% of global revenue and 30% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

Middle East and Africa holds 5% of the global durable medical equipment market in 2025, worth USD 11.75 billion with USD 20.8 billion projected for 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.

Its share rises to 5.2% over the forecast period, at a pace above the 6.12% global rate, so this region warrants separate treatment and should not be scaled off the total.

Segment composition follows the global pattern: Wheelchairs largest at 14% of 2025 revenue, Monitoring And Therapeutic Devices fastest at 8.52%. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.

30.04% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 3.53 billion, rising to USD 6.24 billion by 2034. 30.04% of the region in the base year makes it the largest market here without making it the region. Set against USD 11.75 billion and USD 20.8 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Composition here matches the global split: the largest line is Wheelchairs at 14% of 2025 revenue, easing to 12.5% by 2034, and the fastest is Monitoring And Therapeutic Devices at 8.52%, from 8% to 9.8%. Because the country carries 30.04% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. The full report reports Saudi Arabia by product separately.

In Saudi Arabia, durable medical equipment falls under the Saudi Food and Drug Authority's medical device framework, which follows a risk-based classification approach aligned with the international harmonization model many regulators in the region reference. Suppliers must obtain a Medical Device Marketing Authorization before a product can be sold, supported by evidence of conformity with recognized international standards and a compliant quality management system. Establishment licensing applies to local manufacturers, importers, and distributors alike. Labelling must appear in Arabic alongside English, stating intended use, storage conditions, and any warnings relevant to equipment used in a home or clinical setting.

Competition in Saudi Arabia runs between the suppliers this study tracks: Invacare Corporation, ArjoHuntleigh, Stryker Corporation, Hill Rom, Inc., Drive Medical, GF Health Products, Inc., Sunrise Medical, Medline Industries, Hill Rom, Inc., Carex Health Brands, Inc, Becton, Dickinson and Company, General Electric Company, Medtronic PLC, Compass Health Brands, Getinge AB and Resmed Inc.. Two different problems sit on the same axis: holding Wheelchairs at 14% of 2025 revenue, and taking Monitoring And Therapeutic Devices while it grows at 8.52%. Weighting toward Middle East and Africa means competing for 5% of 2025 global revenue, a base of USD 11.75 billion moving to USD 20.8 billion across the forecast period.

Within Middle East and Africa, South Africa accounts for 20% of regional revenue and 1% of the global total, worth USD 2.35 billion in 2025 and USD 4.16 billion by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Product, End-use, Distribution Channel, Payment/Reimbursement Type, Age Group, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.